Observations on the Risk of Resistance With the Extended Use of Vancomycin | Infectious Diseases | JAMA Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
Uttley  AHCollins  CHNaidoo  JGeorge  RC Vancomycin-resistant enterococci [letter].  Lancet. 1988;157- 58Google ScholarCrossref
2.
Not Available, Nosocomial enterococci resistant to vancomycin—United States, 1989-1993.  MMWR Morb Mortal Wkly Rep. 1993;42597- 599Google Scholar
3.
Moellering Jr  RC Emergence of enterococcus as a significant pathogen [review].  Clin Infect Dis. 1992;141173- 1176Google ScholarCrossref
4.
Schaberg  DRCulver  DHGaynes  RP Major trends in the microbial etiology of nosocomial infection.  Am J Med. 1991;91 ((3B)) 72S- 75SGoogle ScholarCrossref
5.
Shlaes  DM Vancomycin-resistant bacteria [editorial].  Infect Control Hosp Epidemiol. 1992;13193- 194Google ScholarCrossref
6.
McManus  ATMason Jr  ADMcManus  WFPruitt Jr  BA Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center.  Eur J Clin Microbiol. 1985;4219- 223Google ScholarCrossref
7.
McManus  ATMason Jr  ADMcManus  WFPruitt Jr  BA What's in a name? Is methicillin-resistant Staphylococcus aureus just another S aureus when treated with vancomycin?  Arch Surg. 1989;1241456- 1459Google ScholarCrossref
8.
Shirani  KZMcManus  ATVaughan  GMMcManus  WFPruitt Jr  BAMason Jr  AD Effects of environment on infection in burn patients.  Arch Surg. 1986;12131- 36Google ScholarCrossref
9.
McManus  ATMason Jr  ADMcManus  WFPruitt Jr  BA A decade of reduced gram-negative infections and mortality associated with improved isolation of burned patients.  Arch Surg. 1994;1291306- 1309Google ScholarCrossref
10.
Mozingo  DWMcManus  ATKim  SHPruitt Jr  BA Incidence of bacteremia after burn wound manipulation in the early postburn period.  J Trauma. 1997;421006- 1011Google ScholarCrossref
11.
National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Susceptibility Not Available. Vol 18 Wayne, Pa National Committee for Clinical Laboratory Standards1998;18NCCLS document M100-S8Google Scholar
12.
National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Susceptibility Not available. Vol 18 Wayne, Pa National Committee for Clinical Laboratory Standards1998;22Google Scholar
13.
Murray  BE Diversity among multidrug-resistant enterococci.  Emerg Infect Dis. 1998;41- 14Google ScholarCrossref
14.
Leclercq  RDerlot  EWeber  MDuval  JCourvalin  P Transferable vancomycin and teicoplanin resistance in Enterococcus faecium Antimicrob Agents Chemother. 1989;3310- 15Google ScholarCrossref
15.
Noble  WCVirani  ZCree  RG Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus FEMS Microbiol Lett. 1992;72195- 198Google ScholarCrossref
16.
Hospital Infection Control Practices Advisory Committee (HICPAC), Recommendations for preventing the spread of vancomycin resistance.  Infect Control Hosp Epidemiol. 1995;16105- 113[published erratum appears in Infect Control Hosp Epidemiol. September 1995;16:498].Google ScholarCrossref
17.
Davis  JMHuycke  MMWells  CL  et al.  Surgical Infection Society position on vancomycin-resistant Enterococcus.  Arch Surg. 1996;1311061- 1068Google ScholarCrossref
Paper
November 1998

Observations on the Risk of Resistance With the Extended Use of Vancomycin

Author Affiliations

From the US Army Institute of Surgical Research, Fort Sam Houston, Tex.

Arch Surg. 1998;133(11):1207-1211. doi:10.1001/archsurg.133.11.1207
Abstract

Objective  To document the risk of the development of vancomycin-resistant bacteria in a population of seriously burned patients during a 10-year period of common vancomycin hydrochloride use.

Design  Retrospective study.

Setting  The US Army Institute of Surgical Research, Burn Center, Fort Sam Houston, Tex.

Population and Methods  Microbiology, infection, and antibiotic use records collected during the hospitalization of 2266 consecutively admitted seriously burned patients were reviewed. Vancomycin was the primary therapeutic agent used for gram-positive infections and was also used as a perioperative prophylactic antibiotic during burn wound excision. This policy was established prior to this review because of a high incidence of methicillin-resistant Staphylococcus aureus colonization and an anecdotal association of increased β-lactam resistance in endemic gram-negative pathogens associated with the use of penicillinase-resistant penicillins and cephalosporins.

Main Outcome Measures  Isolation of vancomycin-resistant enterococci (VRE) or other gram-positive organisms resistant to vancomycin.

Results  Examinations of 15,125 gram-positive isolates, including 957 enterococci, for in vitro sensitivity to vancomycin yielded 3 VRE isolates in 3 patients. Vancomycin was used prior to VRE isolation in one of these patients. Resistance was found in 3 other organisms (2 Corynebacterium species, 1 Lactobacillus species). Vancomycin was used prior to these isolations in 2 of 3 patients. None of the vancomycin-resistant organisms was associated with infection and all 6 patients survived. Vancomycin-resistant enterococci or other vancomycin-resistant gram-positive organisms were not found in 663 patients treated with vancomycin for documented gram-positive infections or in 1027 patients where perioperative vancomycin was used.

Conclusion  Use of vancomycin as the primary therapeutic agent in seriously burned patients was not associated with increased risk of VRE isolation or VRE infection.

×